Eight of 14 (57%) CD-associated adenocarcinomas were positive for CLDN18, and 5 (36%) lesions showed ≥ 40% extent expression and 2 (14%) of them showed ≥ 75% extent expression. Here, CLDN18 is linked to adenocarcinoma.